The cardiac troponins are generally acknowledged as the biochemical gold standard for the detection of myocardial necrosis. Current guidelines suggest the use of the 99th percentile of troponin concentrations from a healthy reference population as a cutoff for diagnostic and prognostic assessment (1, 2 ) . With the implementation of assays with improved analytical sensitivity, however, the reliable determination of troponin even at concentrations well below the previously defined 99th percentile values has become possible (3, 4 ) . Concentrations below the 99th percentile measured with several different assays have been shown to provide robust prognostic information (4 -7 ) .
Determination of the previously established 99th percentile was likely influenced by the limits of sensitivity of the assays as well as the characteristics of the reference population from which it had been determined. To address this issue, we used an improved iteration of the commercially available Beckman Coulter assay to establish 75th, 90th, 97.5th, and 99th percentiles for cardiac troponin I (cTnI) 4 in apparently healthy elderly individuals participating in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. The prevalence of cTnI elevations above these percentiles, differences potentially related to sex, and prognostic implications were then assessed in patients stabilized after a recent episode of non-ST-elevation acute coronary syndrome (ACS) who participated in the Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC II) trial.
Materials and Methods
The primary aim of the PIVUS study was to investigate mechanisms of endothelial function and arterial compliance in an elderly general population (8 ) . All individuals age 70 years living in Uppsala, Sweden, were eligible for participation. Potential study participants were chosen in a randomized way from the register of community inhabitants. Of the 2025 individuals invited, 1016 participated in the study between 2001 and 2005. All participants recorded their medical history, smoking habits, and regular medication, and underwent echocardiography.
The FRISC II trial was a prospective multicenter study, conducted between 1996 and 1998, in which a total of 3489 patients with non-ST-elevation ACS were randomized in a factorial design to an early invasive or noninvasive strategy and to 3 months treatment with dalteparin or placebo (9, 10 ) . Patients were eligible for study inclusion if they had symptoms of unstable coronary artery disease with objective signs of myocardial ischemia such as changes found on electrocardiograph (ECG) (ST-segment depression Ն0.1 mV or T-wave inversion Ն0.1 mV) or increased biochemical markers of myocardial necrosis. Patients were followed with outpatient visits at 6 (4 -7 ) weeks, and 3 and 6 months, and by telephone contacts at 12 and 24 months. Thereafter and up to 5 years after randomization, all information on events was obtained from national registries run by the Swedish Health Authority (10 ) . The present analysis included 1380 patients who participated in a blood-sampling program in which blood samples were collected 6 weeks, 3 months, and 6 months after randomization at selected study centers. Patients with an acute myocardial infarction (AMI) or a revascularization procedure within14 days before blood sampling at 6 months were excluded. Mortality occurring after the 6-month sampling period was used as an endpoint.
Written informed consent was obtained from all participants of both studies, and the study protocols were approved by all local ethics committees. cTnI was determined in both studies from frozen (-70°C), not previously thawed samples of EDTAplasma by using the current version of the Access AccuTnI assay (Beckman Coulter). Following recent modifications by the manufacturer, the signal-to-dose relationship of this assay had been improved, thereby providing more robust results at the low end of its range compared to the previous version of the assay. Accordingly, the lower limit of detection of the assay was found to be 0.006 g/L, and the lowest concentrations measurable with CVs of Յ10% and Յ20% were 0.014 g/L and 0.008 g/L, respectively (4 ). Measurements in unthawed duplicate cTnI samples from the FRISC II study (n ϭ 31) showed a linear correlation to samples used in a previous analysis (r 2 ϭ 0.99), indicating that no in vitro cTnI degradation processes had occurred during the time of storage (see Supplemental Fig. 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem. org/content/vol55/issu1).
N-terminal probrain natriuretic peptide (NT-pro-BNP) was determined in both studies by using the Elecsys pro-BNP sandwich immunoassay on Elecsys 2010 instruments (Roche Diagnostics). The analytical range of this assay is 5-35 000 ng/L. Plasma creatinine was analyzed in the PIVUS by study using an Architect ci8200 analyzer (Abbott Laboratories) and locally at the time of randomization in the FRISC II-study. In both studies creatinine-clearance was calculated according to the Cockcroft-Gault formula (11 ) .
Clinical risk factors were defined as follows: Participants were considered to have hypertension if they were undergoing antihypertensive treatment or had blood pressure Ͼ140/90 mm Hg at rest (PIVUS), or if they were undergoing antihypertensive treatment (FRISC II). Diabetes was considered to be present in patients with fasting glucose Ͼ6.1 mmol/L or who were undergoing antidiabetic treatment including diet (PIVUS), or with fasting glucose Ͼ6.1 mmol/L or antidiabetic treatment at 6-month follow-up (FRISC II). Hyperlipidemia was considered present in individuals with LDL-cholesterol Ͼ3.5 mmol/L, serum triglycerides Ͼ1.7 mmol/L, or undergoing antihyperlipidemic treatment (PIVUS), or with total cholesterol Ͼ5.0 mmol/L or undergoing antihyperlipidemic treatment at 6-month follow-up (FRISC II).
Previous AMI was identified on the basis of selfreported history (PIVUS) or history of AMI before the index event or AMI as index event, defined as cardiac troponin T Ͼ0.035 g/L (Elecsys 2010; 10% CV level) (12 ) , or AMI after randomization and before 6-month follow-up (FRISC II). Previous coronary revascularization was determined by self-reported history (PIVUS) or history of coronary revascularization or revascularization after randomization and before 6-month follow-up (FRISC II). Congestive heart failure was identified by self-reported history (PIVUS) or pharmacologically treated heart failure or left-ventricular ejection fraction Ͻ0.45, assessed by echocardiography during the index hospitalization (FRISC II).
Additional definitions applied for analyses in the PIVUS study were cardiovascular disease, defined by previous AMI, previous revascularization, congestive heart failure, previous stroke (self reported), or hypertension. Normal ECG was defined as no evidence of ST-segment depression (Minnesota codes 4 -1 and 4 -2), T-wave inversion (Minnesota codes 5-1, 5-2, or 5-3), pathologic Q-waves (Minnesota code 1-1), or left bundle-branch block (Minnesota code 7-1) (13 ). Left ventricular hypertrophy was defined as left ventricular mass index on echocardiography Ͼ116 g/m 2 in men or Ͼ104 g/m 2 in women (14 ) . Increased NT-pro-BNP levels were defined as NT-pro BNP Ͼ210 g/L in men or Ͼ250 g/L in women (15, 16 ) .
We established the 75th, 90th, 97.5th, and 99th percentiles for cTnI by using the weighted average method [Statistical Package for Social Sciences (SPSS) version 14.0] in 2 different subsets from the PIVUS study, first in all participants and second in participants without cardiovascular disease, with a normal ECG, without left ventricular hypertrophy, and with nonincreased levels of NT-pro-BNP. The 95% CIs of the cTnI percentiles were estimated with the bootstrap (percentile) method by using 10000 bootstrap samples.
The prevalence of cTnI levels above the percentiles derived from the healthiest subset of PIVUS participants was then assessed in the FRISC II study in samples obtained at 6 months. The relative importance of sex as a contributor to detectable cTnI levels was evaluated in both studies by multivariable logistic regression analysis (model 1) with adjustment for age (FRISC II study only), congestive heart failure, diabetes, hyperlipidemia, previous smoking, previous AMI, previous coronary revascularization, creatinine clearance, and NT-pro -BNP levels (model 2). Because NT-pro-BNP values were highly skewed, we performed logarithmic transformation on these data before entering them into model 2.
Continuous variables are described as medians and 25th and 75th percentiles. Categorical variables are expressed as frequencies and percentages. Differences regarding categorical variables between groups were analyzed with the Pearson 2 test and within groups with the McNemar test. The prognostic importance of cTnI levels was evaluated by calculating the sensitivities and specificities for 5-year mortality and by using Cox proportional hazard models. We calculated the 95% CIs for the sensitivities and specificities by using a statistical program available on the internet site of the Southwest Oncology Group Statistical Center (17 ) .
For all comparisons, a 2-sided P-value of Ͻ0.05 was considered statistically significant. Data analysis was performed using the SPSS 14.0 software program. The 95% CIs for cTnI percentiles were calculated using the R Development Core Team statistical software (R Foundation for Statistical Computing).
Results

PIVUS STUDY
cTnI results were available for 1005 study participants. The clinical characteristics in relation to sex are shown in Table 1 . In total, 520 participants (48% men) had neither cardiovascular disease, left ventricular hypertrophy, ECG abnormalities, nor increased NT-pro-BNP levels. cTnI levels ranged from 0.0 to 0.777 g/L in men and from 0.0 to 0.099 g/L in women in the overall group. The cTnI percentiles including 95% CI for the 2 different subsets of study participants are given in Table 2. The 99 th percentile values were 0.044 g/L for the overall group. All assessed percentiles including the 99 th percentiles were significantly higher in men compared to women. The 99th percentile value for individuals without cardiovascular disease, left ventricular hypertrophy, ECG abnormalities, or increased NT-pro-BNP levels was 0.028 g/L, and the 97.5th, 90th and 75th percentiles in this subset were 0.022 g/L, 0.013 g/L and 0.009 g/L, respectively. Only the 75th and 90th percentiles differed significantly between the sexes in this subset, with higher percentile values found in men.
cTnI was more often increased in men compared to women with regard to all tested cutoffs (Table 1) . According to multivariable logistic regression analysis applied to the entire population from the PIVUS study (n ϭ 1 005), male sex was also independently associated with detectable cTnI levels Ͼ0.006 g/L in model 1 [odds ratio (OR) 2.1 (95% CI 1.6 -2.7); P Ͻ 0.001] and model 2 adjusted for several cardiovascular comorbidities and their indicators [OR 2.2 (95% CI 1.7-2.9); P Ͻ 0.001].
FRISC II STUDY
cTnI results were available at 6 months after randomization in 952 patients. The clinical characteristics of this population are given in Table 1 . cTnI levels ranged from 0.0 to 1.815 g/L in men and from 0.0 to 1.665 g/L in women, with a total of 588 patients (61.7%) having detectable cTnI levels Ͼ0.006 g/L. Application of the 99th percentile determined in the healthiest subset of PIVUS participants (i.e., cTnI Ͼ0.028 g/L) resulted in an increased rate of increased cTnI levels compared to the 99th percentile of 0.044 g/L derived from the entire PIVUS population [75 patients (7.9%) vs 42 patients (4.4%); P Ͻ 0.001].
Men had higher rates of cTnI elevation compared to women with regard to the lower limit of detection and the 75th and 90th percentiles but not regarding higher percentiles (Table 1) . As in the PIVUS study, male sex was independently associated with the prevalence of detectable cTnI concentrations Ͼ0.006 g/L [model 1, OR 1.6 (95% CI 1.2-2.1); P ϭ 0.002; model 2, OR 2.0 (95% CI 1.4 -2.9); P Ͻ 0.001].
The implications of the sex-specific cutoffs derived from the healthiest subset of PIVUS participants were evaluated by using the 90th percentiles (i.e., cTnI Ͼ0.014 g/L in men, cTnI Ͼ0.011 g/L in women) and 99th percentiles (i.e., cTnI Ͼ0.033 g/L in men, cTnI Ͼ0.025 g/L in women). We did not consider the 75th percentiles because at this low cTnI concentration the subtle differences between the sexes might have been influenced by the relative analytical imprecision of the AccuTnI assay. Application of the sex-specific 99th percentiles instead of an overall single 99th percentile lowered the rate of cTnI positivity at 6 months from 7.9% to 6.9% (P ϭ 0.02). This effect was mainly due to the reclassification of 1.6% of all men included in this analysis from cTnI positive to cTnI negative, i.e., men with minor cTnI elevations who were cTnI positive by the single 99th percentile of 0.028 g/L and cTnI negative by the sex-specific 99th percentile of 0.033 g/L. Of all women with cTnI concentrations in the range 0.026 -0.028 g/L, 0.7% were reclassified from cTnI negative to cTnI positive on the basis of sex-specific 99th percentiles. When the sex-specific 90th percentiles were applied instead of a single 90th percentile, only a slightly lower rate of cTnI positivity was noted, a finding that was not statistically significant (25.2% vs 24.0%; P ϭ 0.11).
The prognostic importance of increased cTnI concentrations above the lowest level of detection and the tested single and sex-specific percentiles derived from the healthiest subset of PIVUS participants is demonstrated in Fig. 1 . When we considered the analytical performance of the applied assay, we considered only a single 75th percentile for this analysis. cTnI concentrations predicted 5-year mortality, with the 75th and 90th percentiles being most prognostically useful. The sensitivities of the 75th and 90 th percentiles for mortality were 63.4% (95% CI 48.0%-71.2%) and 47.9% (95% CI 36.3%-59.5%), with corresponding specifici- ties of 61.5% (95% CI 58.5%-65.0%) and 76.7% (95% CI 74.3%-79.8%), respectively. The negative predictive values were 95.4% and 94.8%, with positive predictive values of 11.7% and 14.2%, respectively. The 97.5th and 99th percentiles provided sensitivities for 5-year mortality of 18.3% (95% CI 10.0%-27.8%) and 9.9% (95% CI 3.8%-18.3%) with specificities of 89.1% (95% CI 87.3%-91.5%) and 92.3% (95% CI 90.8%-98.3%), respectively. The negative predictive values for both cutoffs were 93.1% and 92.7%, respectively, and their positive predictive values were 11.9% and 9.3%, respectively. The sex-specific cutoffs were not consistently better for prognostication compared to the single cutoffs, as demonstrated by the large overlap of 95% CIs for the 5-year mortality hazard ratios [ Fig. 1 ; P ϭ 1.00 for any comparison of single and sex-specific cutoffs (McNemar test)].
Discussion
For clinical decision-making in patients with ACS, guideline groups recommend the use of a troponin cutoff corresponding to the 99th percentile derived from a healthy reference population (1, 2 ) . However, our data, with the use of a highly sensitive assay that allows for the reliable detection of cTnI levels below this threshold, unmask several important issues that require critical reflection. Our results demonstrate that the cTnI 99th percentile strongly depends on the selection of individuals forming the reference population. The use of stricter criteria among apparently healthy 70-year-old individuals from the PIVUS study resulted in a decrease of the 99th percentile values from 0.044 to 0.028 g/L.
In addition, we found 1.3-fold to 2.6-fold higher 99th percentiles in men compared to women, depending on the chosen subset of participants from the PIVUS study. This result was mainly attributable to particularly high cTnI levels in some men with cardiovascular disease. These results are in line with those of previous studies demonstrating that mean troponin concentrations differ between the sexes when analyzed with assays with improved analytical sensitivity (18, 19 ) . This phenomenon may depend on more pronounced myocardial apoptotic processes in men (20, 21 ) , differences in the frequency and/or types of cardiovascular comorbidities potentially capable of increasing troponin values, or intrinsic differences in the amount of troponin between the male and female myocardium (22 ) . Although this finding suggests an advantage to the use of sex-specific troponin cutoffs, our results indicate that a single cutoff is sufficient given the close relation to 5-year mortality for both types of cutoffs at the tested thresholds. Establishment of troponin cutoffs in a healthy and younger reference population than the PIVUS participants will probably also diminish differences of cTnI concentrations between men and women, thereby making sex-specific cutoffs obsolete.
Our results highlight an additional issue, suggesting that the assays currently in use are not nearly as sensitive as might be optimal for clinical purposes. That troponin levels even below the 99th percentile are useful for the detection of cardiac disease or definition of risk has been demonstrated in previous studies. These studies, however, applied assays with 10% CV levels above or in the same range as the 99th percentile (6, 23 ) . Thus, some caution is required when interpreting these results, owing to the imperfect analytical assay precision at lower troponin concentrations. Our results are an important addition to the existing literature because the superior analytical performance of the highly sensitive assay used in our analysis allowed for the reliable determination of risk associated with troponin concentrations below the 99th percentile. Our data raise the question of what troponin cutoff should be regarded as the most appropriate biochemical criterion for decision-making in ACS, particularly because recent data suggest that normal values are substantially lower than measured by any of the currently available assays (3 ) .
For the recently modified AccuTnI assay, the 10% CV level is 0.014 g/L, a value that is close to the 90th percentile established in the healthiest subset from the Estimated hazard ratios (HR) and corresponding 95% CIs for single and sex-specific cutoffs are given. LLD indicates lowest level of detection; perc, percentile PIVUS study. The 90th percentile was associated with higher hazard ratios for 5-year mortality, suggesting an increased clinical utility to this value in a concentration range for which the sex-related differences also lost their relative importance. The failure of cutoffs below the 90th percentile to improve risk prediction may be related to the relative imprecision of the AccuTnI assay at these very low thresholds or the fact that these low cTnI concentrations represent only physiologic cardiomyocyte turnover.
Our findings are at variance with those of some other studies demonstrating an increasing mortality with higher troponin cutoffs (5, 6, 24 ) . We can not exclude the possibility that a probable beneficial effect by coronary revascularization attenuated the prognostic value of high cTnI cutoffs in patients with more severe cardiac disease, i.e., patient subgroups known to have a higher prevalence of cTnI elevation (7, 25, 26 ) .
Regarding the clinical utility of cTnI cutoffs below the 99th percentile, lower diagnostic cutoffs undoubtedly will result in an increased rate of detection of cTnI elevations that may be more likely to be attributable to chronic rather than acute processes (7 ) or be difficult to explain. This possibility is reflected by the 62% rate of detectable cTnI concentrations in FRISC II participants at 6 months after randomization and by recent data from the Val-HeFT (Valsartan Heart-Failure Trial) study, which revealed cardiac troponin T concentrations Ն0.001 g/L in 92% of patients with stable heart failure assessed by use of another highly sensitive assay (25 ) . For that reason, the importance of a significant change in serially measured troponin concentrations and the strict adherence to complementary criteria for defining AMI in an acute setting should be emphasized whenever the use of a lowered troponin cutoff is contemplated.
LIMITATIONS
Because we established the percentiles of cTnI in a population of 70-year-old individuals, we could not evaluate potential influences of age on the distribution of cTnI levels, an influence that has been reported for at least 1 assay (27 ) . Given the results of the present analysis, however, the relationship between age and troponin concentrations may also be related to the increasing prevalence of subclinical cardiovascular disease in elderly individuals.
